FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression
Articolo
Data di Pubblicazione:
2023
Citazione:
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression / Sternberg, C.N., Petrylak, D.P., Bellmunt, J., Nishiyama, H., Necchi, A., Gurney, H., Lee, J., Van Der Heijden, M.S., Rosenbaum, E., Penel, N., Pang, S., Li, J., García Del Muro, X., Joly, F., Pápai, Z., Bao, W., Ellinghaus, P., Lu, C., Sierecki, M., Coppieters, S., et al.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 41:3(2023), pp. 629-639. [10.1200/JCO.21.02303]
Abstract:
Rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor, showed promising phase I efficacy and safety in patients with advanced urothelial carcinoma (UC) with FGFR1-3 mRNA overexpression. We assessed rogaratinib efficacy and safety versus chemotherapy in patients with FGFR mRNA-positive advanced/metastatic UC previously treated with platinum chemotherapy.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Sternberg, Cora N; Petrylak, Daniel P; Bellmunt, Joaquim; Nishiyama, Hiroyuki; Necchi, Andrea; Gurney, Howard; Lee, Jae-Lyun; Van Der Heijden, Michiel S; Rosenbaum, Eli; Penel, Nicolas; Pang, See-Tong; Li, Jian-Ri; García Del Muro, Xavier; Joly, Florence; Pápai, Zsuzsanna; Bao, Weichao; Ellinghaus, Peter; Lu, Chengxing; Sierecki, Mitchell; Coppieters, Sabine; Nakajima, Keiko; Ishida, Tatiane Cristine; Quinn, David I
Link alla scheda completa:
Link al Full Text:
Pubblicato in: